Cerevel Therapeutics Holdings, Inc. Share Price
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.96 USD | +0.74% |
|
-.--% | - |
| Market Cap | 819.15Cr 719.46Cr 669.08Cr 613.97Cr 1.15TCr 79TCr 1.17TCr 7.95TCr 3.1TCr 39TCr 3.08TCr 3.01TCr 1,34100Cr | P/E 2022 |
-13.6x | P/E 2023 | -15.9x |
|---|---|---|---|---|---|
| Enterprise Value | 749.61Cr 658.38Cr 612.28Cr 561.85Cr 1.06TCr 72TCr 1.07TCr 7.27TCr 2.84TCr 35TCr 2.81TCr 2.75TCr 1,22700Cr | EV / Sales 2022 |
-
| EV / Sales 2023 | - |
| Free-Float |
93.64% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +0.74% |
| 3 years | 19.59 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/05/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Paul Burgess
PRN | Corporate Officer/Principal | 53 | 20/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 20/01/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 01/08/24 | Issuer sale | Chief Medical Officer | 14,95,399 | 0.8208% | ||
| 01/08/24 | Bain Capital Private Equity LP
| Issuer sale | Company | 6,56,79,781 | 36.0492% | |
| 01/08/24 | Issuer sale | Executive/Senior Manager | 2,22,723 | 0.1222% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | -.--% | +52.46% | 819.15Cr | |
| -1.92% | -1.57% | +48.70% | +84.37% | 5.59TCr | |
| +0.93% | +6.97% | +62.83% | +67.97% | 5.67TCr | |
| -2.71% | -1.92% | -21.69% | -16.17% | 2.33TCr | |
| -0.15% | -0.84% | +3.76% | +424.98% | 2.33TCr | |
| -0.36% | -0.56% | +36.00% | -3.93% | 2.05TCr | |
| -1.34% | +0.51% | +25.02% | -30.27% | 1.78TCr | |
| -1.44% | -1.63% | +37.07% | +589.93% | 1.59TCr | |
| -1.30% | -9.92% | +160.67% | +284.37% | 1.46TCr | |
| -0.37% | -0.89% | +23.74% | +178.66% | 1.4TCr | |
| Average | -0.79% | +0.42% | +37.61% | +163.24% | 2.5TCr | |
| Weighted average by Cap. | -0.77% | +1.42% | +41.27% | +135.65% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | - | - |
| Net income | -35Cr -31Cr -29Cr -26Cr -50Cr -3.39TCr -50Cr -340.94Cr -133.2Cr -1.66TCr -131.96Cr -129.11Cr -5.75TCr | -43Cr -38Cr -35Cr -32Cr -61Cr -4.17TCr -62Cr -419.82Cr -164.02Cr -2.05TCr -162.49Cr -158.99Cr -7.09TCr |
| Net Debt | -52Cr -46Cr -43Cr -39Cr -74Cr -5.04TCr -75Cr -507.5Cr -198.28Cr -2.48TCr -196.42Cr -192.19Cr -8.57TCr | -70Cr -61Cr -57Cr -52Cr -98Cr -6.7TCr -99Cr -674.47Cr -263.51Cr -3.29TCr -261.05Cr -255.42Cr -11TCr |
Employees
355
- Stock Market
- Stocks
- CERE Stock
Select your edition
All financial news and data tailored to specific country editions
